HC Wainwright Lowers Earnings Estimates for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of BridgeBio Pharma in a research note issued to investors on Monday, July 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.38) for the quarter, down from their prior estimate of ($0.37). HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.29) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s FY2026 earnings at ($1.50) EPS and Q1 2027 earnings at $0.11 EPS.

Several other research firms have also recently issued reports on BBIO. Royal Bank Of Canada assumed coverage on BridgeBio Pharma in a research report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price objective on the stock. Truist Financial lifted their target price on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Raymond James Financial cut BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Canaccord Genuity Group started coverage on BridgeBio Pharma in a report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.21.

BridgeBio Pharma Stock Down 2.9%

Shares of BBIO opened at $80.30 on Wednesday. The company has a market capitalization of $15.73 billion, a P/E ratio of -21.47 and a beta of 0.95. The firm has a 50 day moving average of $70.85 and a 200 day moving average of $72.25. BridgeBio Pharma has a twelve month low of $42.09 and a twelve month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. During the same quarter in the previous year, the company posted ($0.88) EPS. The business’s quarterly revenue was up 66.8% on a year-over-year basis.

Insiders Place Their Bets

In other news, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $67.46, for a total transaction of $2,698,400.00. Following the transaction, the chief executive officer owned 535,686 shares in the company, valued at $36,137,377.56. This trade represents a 6.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Trimarchi sold 13,651 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $65.08, for a total value of $888,407.08. Following the transaction, the chief financial officer owned 359,194 shares of the company’s stock, valued at approximately $23,376,345.52. This trade represents a 3.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 432,117 shares of company stock worth $32,633,740 in the last 90 days. Insiders own 14.23% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds have recently made changes to their positions in the business. First Bank & Trust raised its stake in BridgeBio Pharma by 1.6% during the 2nd quarter. First Bank & Trust now owns 8,797 shares of the company’s stock valued at $655,000 after purchasing an additional 142 shares during the period. GAMMA Investing LLC boosted its stake in BridgeBio Pharma by 13.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,646 shares of the company’s stock worth $123,000 after purchasing an additional 199 shares during the period. Harbor Investment Advisory LLC bought a new position in BridgeBio Pharma in the 2nd quarter worth approximately $137,000. Parallel Advisors LLC grew its holdings in BridgeBio Pharma by 552.6% during the 1st quarter. Parallel Advisors LLC now owns 894 shares of the company’s stock valued at $66,000 after buying an additional 757 shares in the last quarter. Finally, Avidity Partners Management LP purchased a new stake in BridgeBio Pharma during the 1st quarter valued at approximately $711,000. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.